Cover Image
市場調查報告書

C型肝炎治療藥的價格設定、醫療費償付

Hepatitis C Pricing and Reimbursement

出版商 Datamonitor Healthcare 商品編碼 342053
出版日期 內容資訊 英文 74 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
C型肝炎治療藥的價格設定、醫療費償付 Hepatitis C Pricing and Reimbursement
出版日期: 2015年01月30日 內容資訊: 英文 74 Pages
簡介

C型肝炎治療藥的價格設定、醫療費償付,從2013年12月美國價格1片1,000美元的Savaldi發售以來受到關注。

本報告提供美國,日本及EU的主要5個市場上C型肝炎治療藥的價格設定、醫療費償付趨勢相關資料,也包含市場背景調查。

圖表

摘要整理

市場背景

  • 迎接戲劇性變化的C型肝炎市場
  • C型肝炎治療藥預算的影響引起保險者的阻力
  • 美國、日本及EU主要5個市場上已上市的C型肝炎治療藥
  • 處於後期開發階段的C型肝炎治療藥的開發平台
  • 價格設定的前提條件
  • 參考文獻

美國

  • 價格決策
  • 醫療費償付
  • 參考文獻

日本

  • 高價位授予附加利益或創新
  • 已上市C型肝炎治療藥的價格設定
  • 基於近幾年認證的治療指南的變更
  • 參考文獻

EU的主要5個市場

  • 價格決策
  • 醫療費償付、醫療技術的評估
  • 參考文獻

圖表清單

目錄
Product Code: DMKC0131852

The pricing and reimbursement of hepatitis C therapies has been in the spotlight since the launch of Sovaldi in the US in December 2013 at the price of $1,000 per pill. While Sovaldi's and Harvoni's clinical effectiveness are undisputed, their high prices have prompted widespread criticism from payers, politicians, and patients due to the large budgetary impact of treating all eligible patients, which will exert a significant strain on healthcare systems.

This report addresses the following questions:

  • What reimbursement restrictions have been imposed by US payers and how do they differ between major brands?
  • Which payers have imposed patient prioritization and how do the strategies differ between countries?
  • How are European payers controlling expenditure on hepatitis C drugs?
  • In which markets did Sovaldi have the best outcome of the health technology assessment?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

MARKET CONTEXT

  • 1. The hepatitis C market is undergoing a seismic shift
  • 2. Budgetary impact of hepatitis C therapies is causing payer pushback
  • 3. Marketed hepatitis C products in the US, Japan, and five major EU markets
  • 4. Pipeline hepatitis C treatments in late-stage development
  • 5. Price assumptions
  • 6. Bibliography

US

  • 7. Pricing
  • 8. Reimbursement
  • 9. Bibliography

JAPAN

  • 10. Price premiums are awarded for added benefit or innovation
  • 11. Pricing of launched hepatitis C treatments
  • 12. Treatment guidelines have been changed in the light of recent approvals
  • 13. Bibliography

FIVE MAJOR EU MARKETS

  • 14. Pricing
  • 15. Reimbursement and health technology assessment
  • 16. Bibliography
Back to Top